Integration of high-content screening and untargeted metabolomics for comprehensive functional annotation of natural product libraries

Traditional natural products discovery using a combination of live/dead screening followed by iterative bioassay-guided fractionation affords no information about compound structure or mode of action until late in the discovery process. This leads to high rates of rediscovery and low probabilities of finding compounds with unique biological and/or chemical properties. By integrating image-based phenotypic screening in HeLa cells with high-resolution untargeted metabolomics analysis, we have developed a new platform, termed Compound Activity Mapping, that is capable of directly predicting the identities and modes of action of bioactive constituents for any complex natural product extract library. This new tool can be used to rapidly identify novel bioactive constituents and provide predictions of compound modes of action directly from primary screening data. This approach inverts the natural products discovery process from the existing ‟grind and find” model to a targeted, hypothesis-driven discovery model where the chemical features and biological function of bioactive metabolites are known early in the screening workflow, and lead compounds can be rationally selected based on biological and/or chemical novelty. We demonstrate the utility of the Compound Activity Mapping platform by combining 10,977 mass spectral features and 58,032 biological measurements from a library of 234 natural products extracts and integrating these two datasets to identify 13 clusters of fractions containing 11 known compound families and four new compounds. Using Compound Activity Mapping we discovered the quinocinnolinomycins, a new family of natural products with a unique carbon skeleton that cause endoplasmic reticulum stress.Notwithstanding the historical importance of natural products in drug discovery (1) the field continues to face a number of challenges that affect the relevance of natural products research in modern biomedical science (2). Among these are the increasing rates of rediscovery of known classes of natural products (3–6) and the high rates of attrition of bioactive natural products in secondary assays due to limited information about compound modes of action in primary whole-cell assays (7). Although pharmaceutical companies recognize that natural products are an important component of drug discovery programs because of the different pharmacologies of natural products and synthetic compounds (8), there is a reluctance to return to “grind and find” discovery methods (9). Therefore, there is a strong need for technologies that address these issues and provide new strategies for the prioritization of lead compounds with unique structural and/or biological properties (10).Natural product drug discovery is challenging in any assay system because extract libraries are typically complex mixtures of small molecules in varying titers, making it difficult to distinguish biological outcomes (11). This is compounded by issues of additive effects of multiple bioactive compounds and the presence of nuisance compounds that cause false positives in assay systems (12). To address these issues, our laboratory has recently developed several image-based screening platforms that are optimized for natural product discovery (13–16). The cytological profiling platform optimized by Schulze and coworkers characterizes the biological activities of extracts using untargeted phenotypic profiling. These phenotypic profiles are compared with natural products extracts and a training set of compounds with known modes of action to characterize the bioactivity landscape of the screening library (17, 18). This cytological profiling tool forms the basis of the biological characterization component of the Compound Activity Mapping platform, as described below.In the area of chemical characterization of natural product libraries, untargeted metabolomics is gaining attention as a method for evaluating chemical constitution (3, 19–22). Modern “genes-to-molecules” and untargeted metabolomics approaches taking advantage of principal component analysis and MS² spectral comparisons have also been developed to quickly dereplicate complex extracts and distinguish noise and nuisance compounds from new molecules (23–27). Unfortunately, although these techniques are well suited to the discovery of new chemical scaffolds, they are unable to describe the function or biological activities of the compounds they identify. Therefore, there is still a need for new approaches to systematically identify novel bioactive scaffolds from complex mixtures.To overcome some of these outstanding challenges we have developed the Compound Activity Mapping platform to integrate phenotypic screening information from the cytological profiling assay with untargeted metabolomics data from the extract library (Fig. 1). By correlating individual mass signals with specific phenotypes from the high-content cell-based screen (Fig. 2), Compound Activity Mapping allows the prediction of the identities and modes of action of biologically active molecules directly from complex mixtures, providing a mechanism for rational lead selection based on desirable biological and/or chemical properties. To evaluate this platform for natural products discovery we examined a 234-member extract library, from which we derived 58,032 biological measurements (Fig. 1C) and 10,977 mass spectral features (Fig. 1A). By integrating and visualizing these data we created a Compound Activity Map for this library composed of 13 clusters containing 16 compounds from 11 compound classes (Fig. 3). This integrated data network enabled the discovery of four new compounds, quinocinnolinomycins A–D (1–4, Fig. 4), which are the first examples to our knowledge of microbial natural products containing the unusual cinnoline core (Fig. 5). Clustering the cytological profiles of the quinocinnolinomycins with those of the Enzo library training set suggests that these compounds induce endoplasmic reticulum (ER) stress and the protein unfolding response.Open in a separate windowFig. 1.Overview of Compound Activity Mapping. (A) Representation of the chemical space in the tested extract library. The network displays extracts (light blue) connected by edges to all m/z features (red) observed from the metabolomics analysis, illustrating the chemical complexity of even small natural product libraries. (B) Histograms of activity and cluster scores for all m/z features with cutoffs indicated as red lines (for full-size histograms see SI Appendix, Fig. S5). (C) Compound Activity Map, with the network displaying only the m/z features predicted to be associated with consistent bioactivity, and their connectivity to extracts within the library. (D) Expansion of the staurosporine cluster (dotted box in C) with extract numbers and relevant m/z features labeled.Open in a separate windowFig. 2.Determination of synthetic fingerprints and cluster and activity scores. (A) Table of Pearson correlations for the cytological profiles between all extracts containing a specific m/z feature (m/z of 489.1896, rt of 1.59). In each cytological profile, yellow stripes correspond to positive perturbations in the observed cytological attribute and blue stripes correspond to negatively perturbed attributes. The cluster score is determined by calculating the average of the Pearson correlation scores for all relevant extracts. (B) Calculated synthetic fingerprint and activity score for feature (m/z of 489.1896, rt of 1.59). Synthetic fingerprints are calculated as the averages of the values for each cytological attribute to give a predicted cytological profile for each bioactive m/z feature in the screening set.Open in a separate windowFig. 3.Annotated Compound Activity Map. An expanded view of the Compound Activity Map from Fig. 1C, with the extracts and m/z features separated into subclusters and colored coded using the Gephi modularity function. Each bioactive subcluster is composed of extracts containing a family of compounds with a defined biological activity. The Compound Activity Map is annotated with a representative molecule from each of the families of compounds that have been independently confirmed by purification and chemical analysis.Open in a separate windowFig. 4.The prioritization, isolation, and confirmation of the quinocinnolinomycins A–D (1–4). (A) Bioactive m/z features plotted on a graph of activity score vs. cluster score. The color of the dot corresponds to the retention time of the m/z feature with the color bar and scale below in minutes. (B) Isolated cluster from Fig. 1C and Fig. 3 containing both the relevant extracts (blue) and bioactive m/z features (red). (C) HPLC trace of extract RLPA-2003E and the isolation of quinocinnolinomycins A–D (highlighted with blue boxes on HPLC trace). (D) Cell images of pure compounds screened as a twofold dilution series for quinocinnolinomycins A and B in both stain sets compared with images of vehicle (DMSO) wells. (E) Comparison of the synthetic and actual cytological fingerprints of the pure compounds is presented below the relevant images, demonstrating the relationship between experimental and calculated cytological profiles for these two metabolites.Open in a separate windowFig. 5.Structure elucidation of quinocinnolinomycins A–D (1–4). (A) Structures of quinocinnolinomycins A–D. (B) Key NMR correlations used in the structure elucidation of quinocinnolinomycin A. COSY correlations are indicated by bold lines. Heteronuclear multiple-bond correlations are indicated by curved arrows. (C) ∆δ^SR values for the Mosher’s α-methoxy-α-trifluoromethylphenylacetic acid (MTPA) ester analysis of the secondary alcohol in quinocinnolinomycin A (1) to assign the absolute configuration at position C11.